Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03692429
Title alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells (alloSHRINK)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Celyad Oncology SA

colon adenocarcinoma

rectum adenocarcinoma


Fluorouracil + Leucovorin + NKR-2 cells + Oxaliplatin

Fluorouracil + Irinotecan + Leucovorin + NKR-2 cells

Age Groups: adult | senior
Covered Countries USA | BEL

No variant requirements are available.